South Korea · Delayed Price · Currency is KRW AriBioLab Statistics
Total Valuation
AriBioLab has a market cap or net worth of KRW 73.82 billion. The enterprise value is 64.36 billion.
| Market Cap | 73.82B |
| Enterprise Value | 64.36B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
AriBioLab has 28.01 million shares outstanding. The number of shares has increased by 0.14% in one year.
| Current Share Class | 28.01M |
| Shares Outstanding | 28.01M |
| Shares Change (YoY) | +0.14% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 1.44% |
| Owned by Institutions (%) | n/a |
| Float | 20.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 426.29 |
| PB Ratio | 7.46 |
| P/TBV Ratio | 7.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.92, with a Debt / Equity ratio of 0.63.
| Current Ratio | 1.92 |
| Quick Ratio | 1.65 |
| Debt / Equity | 0.63 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.67 |
| Interest Coverage | -7.40 |
Financial Efficiency
Return on equity (ROE) is -92.28% and return on invested capital (ROIC) is -33.73%.
| Return on Equity (ROE) | -92.28% |
| Return on Assets (ROA) | -25.28% |
| Return on Invested Capital (ROIC) | -33.73% |
| Return on Capital Employed (ROCE) | -113.11% |
| Weighted Average Cost of Capital (WACC) | 6.64% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -5.12% in the last 52 weeks. The beta is 0.20, so AriBioLab's price volatility has been lower than the market average.
| Beta (5Y) | 0.20 |
| 52-Week Price Change | -5.12% |
| 50-Day Moving Average | 2,421.46 |
| 200-Day Moving Average | 2,907.42 |
| Relative Strength Index (RSI) | 59.15 |
| Average Volume (20 Days) | 282,017 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AriBioLab had revenue of KRW 173.16 million and -14.42 billion in losses. Loss per share was -536.24.
| Revenue | 173.16M |
| Gross Profit | 160.16M |
| Operating Income | -12.97B |
| Pretax Income | -14.42B |
| Net Income | -14.42B |
| EBITDA | -12.55B |
| EBIT | -12.97B |
| Loss Per Share | -536.24 |
Balance Sheet
The company has 15.64 billion in cash and 6.19 billion in debt, with a net cash position of 9.45 billion or 337.41 per share.
| Cash & Cash Equivalents | 15.64B |
| Total Debt | 6.19B |
| Net Cash | 9.45B |
| Net Cash Per Share | 337.41 |
| Equity (Book Value) | 9.89B |
| Book Value Per Share | 367.79 |
| Working Capital | 8.88B |
Cash Flow
In the last 12 months, operating cash flow was -9.17 billion and capital expenditures -31.74 million, giving a free cash flow of -9.20 billion.
| Operating Cash Flow | -9.17B |
| Capital Expenditures | -31.74M |
| Depreciation & Amortization | 418.58M |
| Net Borrowing | -11.92B |
| Free Cash Flow | -9.20B |
| FCF Per Share | -328.57 |
Margins
| Gross Margin | 92.49% |
| Operating Margin | -7,491.66% |
| Pretax Margin | -8,327.31% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AriBioLab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.14% |
| Shareholder Yield | -0.14% |
| Earnings Yield | -19.53% |
| FCF Yield | -12.47% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AriBioLab has an Altman Z-Score of -2.98 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.98 |
| Piotroski F-Score | 3 |